iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. Show more
Location: 321 Arsenal Street, Watertown, MA, 02472, United States | Website: https://www.iteostherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
396.1M
52 Wk Range
$4.80 - $18.13
Previous Close
$10.35
Open
$10.39
Volume
1,164,148
Day Range
$10.25 - $10.39
Enterprise Value
-133.7M
Cash
520.4M
Avg Qtr Burn
-24.89M
Insider Ownership
1.14%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Belrestotug (EOS-448) + Dostarlimab (doublet) Details Cancer, Non-small cell lung carcinoma | Failed Discontinued | |
Belrestotug (EOS-448) + Dostarlimab (doublet) + Nelistotug (triplet) Details Cancer, Head and neck squamous cell carcinoma | Failed Discontinued | |
Inupadenant (EOS-850) Details Cancer, Non-small cell lung carcinoma | Failed Discontinued | |
EOS-984 + Pembrolizumab Details Solid tumor/s, Cancer | Failed Discontinued | |
EOS-215 Details Cancer, Solid tumor/s | Failed Discontinued |